Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 3
2011 3
2012 1
2013 3
2014 4
2015 6
2016 2
2017 4
2018 5
2020 3
2021 6
2022 3
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Venetoclax for the treatment of chronic lymphocytic leukemia.
Gentile M, Petrungaro A, Uccello G, Vigna E, Recchia AG, Caruso N, Bossio S, De Stefano L, Palummo A, Storino F, Martino M, Morabito F. Gentile M, et al. Among authors: bossio s. Expert Opin Investig Drugs. 2017 Nov;26(11):1307-1316. doi: 10.1080/13543784.2017.1386173. Epub 2017 Oct 9. Expert Opin Investig Drugs. 2017. PMID: 28972395 Review.
Janus kinase 2 inhibitors in myeloproliferative disorders.
Lucia E, Recchia AG, Gentile M, Bossio S, Vigna E, Mazzone C, Madeo A, Morabito L, Gigliotti V, De Stefano L, Caruso N, Servillo P, Franzese S, Bisconte MG, Gentile C, Morabito F. Lucia E, et al. Among authors: bossio s. Expert Opin Investig Drugs. 2011 Jan;20(1):41-59. doi: 10.1517/13543784.2011.538382. Epub 2010 Dec 4. Expert Opin Investig Drugs. 2011. PMID: 21128825 Review.
Lenalidomide in the treatment of chronic lymphocytic leukemia.
Gentile M, Recchia AG, Vigna E, Mazzone C, Lucia E, Gigliotti V, Bossio S, Madeo A, Morabito L, Servillo P, Franzese S, Caruso N, De Stefano L, Bisconte MG, Gentile C, Morabito F. Gentile M, et al. Among authors: bossio s. Expert Opin Investig Drugs. 2011 Feb;20(2):273-86. doi: 10.1517/13543784.2011.546343. Epub 2011 Jan 10. Expert Opin Investig Drugs. 2011. PMID: 21214505 Review.
Interleukin-17 signaling influences CD8+ T cell immunity and tumor progression according to the IL-17 receptor subunit expression pattern in cancer cells.
Rodriguez C, Araujo Furlan CL, Tosello Boari J, Bossio SN, Boccardo S, Fozzatti L, Canale FP, Beccaria CG, Nuñez NG, Ceschin DG, Piaggio E, Gruppi A, Montes CL, Acosta Rodríguez EV. Rodriguez C, et al. Among authors: bossio sn. Oncoimmunology. 2023 Oct 5;12(1):2261326. doi: 10.1080/2162402X.2023.2261326. eCollection 2023. Oncoimmunology. 2023. PMID: 37808403 Free PMC article.
Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
Vigna E, Recchia AG, Madeo A, Gentile M, Bossio S, Mazzone C, Lucia E, Morabito L, Gigliotti V, Stefano LD, Caruso N, Servillo P, Franzese S, Fimognari F, Bisconte MG, Gentile C, Morabito F. Vigna E, et al. Among authors: bossio s. Expert Opin Investig Drugs. 2011 Apr;20(4):465-93. doi: 10.1517/13543784.2011.559164. Epub 2011 Mar 8. Expert Opin Investig Drugs. 2011. PMID: 21381982 Review.
Promising therapies for the treatment of chronic lymphocytic leukemia.
Morabito F, Recchia AG, Vigna E, De Stefano L, Bossio S, Morabito L, Pellicanò M, Palummo A, Storino F, Caruso N, Gentile M. Morabito F, et al. Among authors: bossio s. Expert Opin Investig Drugs. 2015 Jun;24(6):795-807. doi: 10.1517/13543784.2015.1021920. Epub 2015 Mar 1. Expert Opin Investig Drugs. 2015. PMID: 25728009 Review.
NLRP3-inflammasome activation in male reproductive system diseases.
Perri A, Bossio S, Rago V, Greco EA, Lofaro D, LA Russa A, DI Luigi L, LA Vignera S, Aversa A. Perri A, et al. Among authors: bossio s. Minerva Endocrinol (Torino). 2022 Sep 30. doi: 10.23736/S2724-6507.22.03918-5. Online ahead of print. Minerva Endocrinol (Torino). 2022. PMID: 36177957
COVID-19 patients display changes in lymphocyte subsets with a higher frequency of dysfunctional CD8lo T cells associated with disease severity.
Onofrio LI, Marin C, Dutto J, Brugo MB, Baigorri RE, Bossio SN, Quiróz JN, Almada L, Ruiz Moreno F, Olivera C, Silvera-Ruiz SM, Ponce NE, Icely PA, Amezcua Vesely MC, Fozzatti L, Rodríguez-Galán MC, Stempin CC, Cervi L; ImmunoCovid-CBA; Maletto BA, Acosta Rodríguez EV, Bertone M, Abiega CD, Escudero D, Kahn A, Caeiro JP, Maccioni M, Motrán CC, Gruppi A, Sotomayor CE, Chiapello LS, Montes CL. Onofrio LI, et al. Among authors: bossio sn. Front Immunol. 2023 Sep 21;14:1223730. doi: 10.3389/fimmu.2023.1223730. eCollection 2023. Front Immunol. 2023. PMID: 37809093 Free PMC article.
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
Morabito F, Tripepi G, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Bossio S, Varettoni M, Murru R, Chiarenza A, Visentin A, Condoluci A, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Al-Janazreh H, Vigna E, Martino EA, Cassin R, D Arrigo G, Galimberti S, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G, Monti P, Menichini P, Olivieri J, Cutrona G, Rossi D, Cuneo A, Di Raimondo F, Gaidano G, Polliack A, Trentin L, Foà R, Ferrarini M, Gattei V, Gentile M. Morabito F, et al. Among authors: bossio s. Am J Hematol. 2021 Aug 1;96(8):E269-E272. doi: 10.1002/ajh.26201. Epub 2021 May 3. Am J Hematol. 2021. PMID: 33878220 Free article. No abstract available.
44 results